TOTEM-RRMS: EU register records the end of recruitment in testosterone study
Published by MyelinWatch:
TOTEM-RRMS · TOTEM-RRMS is a Phase 2 study testing testosterone in men with relapsing-remitting MS and low testosterone. MRI scans and clinical measures assess possible effects on nerve protection and myelin.
What is being studied
TOTEM-RRMS is a Phase 2 study testing testosterone in men with relapsing-remitting MS and low testosterone. MRI scans and clinical measures assess possible effects on nerve protection and myelin.
Research stage
Testing whether it helps patients
The study continues without taking new participants.
What we know so far
At the 28 October 2026 check, the EU register (CTIS) listed the study as ongoing with recruitment ended, and recorded the end of recruitment in France on 29 June 2026. ClinicalTrials.gov, last updated 29 June 2025, before that date, still says the study is accepting participants. No study results are posted.
What this means for patients today
According to the EU register, the study is no longer enrolling new participants, and it had no centre in Greece. Testosterone is not an established MS treatment.
- Treatment or approach
- Testosterone • relapsing-remitting MS
- How it is intended to work
- Tests whether testosterone can protect nerves and support repair
- Where the study is running
- Centres in France • none in Greece
- Published by MyelinWatch
- Last substantive MyelinWatch update